Compugen Ltd. (NASDAQ:CGEN) Receives Average Recommendation of “Buy” from Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have been assigned an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $20.71.

Separately, Zacks Investment Research lowered shares of Compugen from a “hold” rating to a “sell” rating in a research note on Tuesday, January 5th.

Get Compugen alerts:

CGEN traded down $1.31 on Tuesday, reaching $10.51. 205,755 shares of the company’s stock were exchanged, compared to its average volume of 1,082,801. Compugen has a twelve month low of $5.94 and a twelve month high of $19.90. The stock has a market cap of $719.09 million, a PE ratio of -27.59 and a beta of 2.52. The stock’s fifty day moving average price is $12.88 and its 200-day moving average price is $14.40.

A number of large investors have recently bought and sold shares of the business. Public Employees Retirement Association of Colorado purchased a new position in shares of Compugen during the 4th quarter worth $58,000. Wells Fargo & Company MN raised its holdings in Compugen by 67.6% in the 4th quarter. Wells Fargo & Company MN now owns 7,756 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 3,127 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Compugen in the fourth quarter valued at about $130,000. Budros Ruhlin & Roe Inc. purchased a new position in Compugen during the third quarter worth about $163,000. Finally, SG Americas Securities LLC boosted its stake in Compugen by 15.4% during the third quarter. SG Americas Securities LLC now owns 11,546 shares of the biotechnology company’s stock worth $188,000 after buying an additional 1,543 shares during the period. Institutional investors own 63.35% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT.

Recommended Story: Why do companies issue stock splits?

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.